Monday 12 November 2001

8:30 - 10:00

 SECOND PLENARY SESSION
 

“SOURCES OF HEALTHCARE INFORMATION IN EUROPE: WHAT RESEARCHERS NEED TO KNOW- OPPORTUNITIES AND CHALLENGES”

An overview of healthcare databases available in Europe will be discussed. Databases from UK, France, Germany, The Netherlands, Belgium, Italy, Spain, Portugal, Norway, Finland, Sweden, and Iceland and well as specific database issues (such as patient confidentiality) will be highlighted.

The Challenges of Healthcare Databases in Europe

Moderator & Speaker: Gérard De Pouvourville PhD, Conference Co-chair & Center for Health Economics and Health Management, Paris, France

Healthcare Databases with Longitudinal Patient Data in Europe 

Speaker: Bernd Brüggenjürgen PhD, Alpha Care GmbH, Celle, Germany

Lessons Learned from Searching and Using Databases in Europe

Speaker: Antoinette Wenk Lang, Boston Scientific International, Cedex, France

The Icelandic Healthcare Database: Confidentiality and Data Access

Speaker: María Heimisdóttir MD, MBA, Director, deCODE genetics, INC, Reykjavík, Iceland.

10:00- 10:15 BREAK
10:15-11:15 CONTRIBUTED PODIUM PRESENTATIONS - SESSION I
(4 Concurrent Topics)

HEALTH POLICY I

HP1   VALIDITY OF THE MINIMUM-DATA-SET-BASED QUALITY INDICATOR FOR DETERMINING THE PREVALENCE OF ANTIPSYCHOTIC MEDICATION USAGE AMONG LOW RISK NURSING HOME RESIDENTS: A STATEWIDE ASSESSMENT
 Monroe DM1, Cortes LL2, Fouladi R3, 1The University of Texas at Austin, Austin, TX, USA; 2Texas Department of Human Services, Austin, TX, USA; 3The University of Texas at MD Anderson Cancer Center, Houston, TX, USA
HP2   TRANSLATING EVIDENCE TO PRACTICE IN BREAST CANCER
 Bloom BS1, Jayadevappa R1, de Pouvourville N2, Chartre S1, 1University of Pennsylvania, Philadelphia, PA, USA; 2University of Paris Medical School, Paris, France
HP3   REGIONAL VARIATION IN PRESCRIPTION USE IN THE UNITED STATES
 Motheral BR, Cox ER, Mager D, Henderson R Express-Scripts, Maryland Heights, MO, USA

CANCER I

CN1   BRIEF ASSESSMENT OF PRIORITY SYMPTOMS IN HORMONE REFRACTORY PROSTATE CANCER (HRPCA)
 Yount SE1, Banik D1, Singh A2, Ashraf T2, Padley RJ2, Dalal M2, Cella D1, 1Evanston Northwestern Healthcare, Evanston, IL, USA; 2Abbott Laboratories, Abbott Park, IL, USA
CN2   RESOURCE CONSUMPTION RELATED TO MUCOSITIS IN LYMPHOMA PATIENTS RECEIVING HIGH-DOSE CHEMOTHERAPY WITH AUTOLOGOUS PBPC TRANSPLANTATION
 Chan WW, Lawless G Amgen Inc, Thousand Oaks, CA, USA
CN   AN ECONOMIC MODEL FOR THE PHARMACOLOGICAL MANAGEMENT OF ADVANCED NON-SMALL CELL LUNG CANCER IN THE US
 Sorensen SV1, Chambers M2, Heyes A3, 1MEDTAP International, Bethesda, MD, USA; 2MEDTAP International UK, London, UK; 3AstraZeneca UK Limited, Macclesfield, UK

CARDIOVASCULAR DISEASE I

CV1   ESTIMATING THE IMPACT OF ANTICOAGULATION QUALITY ON EVENT RATES
 Matchar DB, Samsa GP Duke University, Durham, NC, USA
CV2   A SIX YEAR FOLLOW UP STUDY OF THE RELATIONSHIP BETWEEN MORTALITY, HOSPITALISATION AND ADHERENCE TO STATIN TREATMENT AFTER FIRST MYOCARDIAL INFARCTION
 Wei L, Wang J, Davey P, MacDonald T MEMO, University of Dundee, Dundee, UK
CV3   VASOPEPTIDASE INHIBITOR REDUCES IN-HOSPITAL COSTS FOR CONGESTIVE HEART FAILURE PATIENTS: RESULTS FROM THE IMPRESS TRIAL
 Eisenstein EL1, Nelson CL1, Simon TA2, Smitten AL3, Lapuerta P2, Mark DB1, 1Duke Clinical Research Institute, Durham, NC, USA; 2Bristol-Myers Squibb, Princeton, NJ, USA; 3Yale University School of Medicine, New Haven, CT, USA

COST ESTIMATION

CE1   IMPACT OF CENSORED COST DATA ON THE OUTCOMES OF ECONOMIC EVALUATIONS
 Oostenbrink JB, Al MJ, Rutten-van Mölken MM Institute for Medical Technology Assessment, Rotterdam, Netherlands
CE2   HANDLING MISSING DATA IN STOCHASTIC COST-EFFECTIVENESS ANALYSIS: THE IMPACT OF IMPUTATION METHODS ON ESTIMATES OF THE PHYSICAL QUANTITIES OF MEDICAL CARE RESOURCE USE
 Bell T1, Liu J1, Backhouse M2, 1Research Triangle Institute, Raleigh-Durham, NC, USA; 2Research Triangle Institute, Manchester, UK
CE3   THE COST OF UPPER GASTRODUODENALENDOSCOPY: AN ACTIVITY-BASED APPROACH
 Crott R1, Makris N2, Barkun A3, Fallone C4, 1University of Montreal and EORTC, Brussels, Belgium; 2University of Montreal, Montreal, QC, Canada; 3McGill University Health Center, Montreal, QC, Canada; 4McGill University Health Center, Montreal, QC, Canada
11:15- 1:30 BREAK
11:30-12:30 CONTRIBUTED PODIUM PRESENTATIONS - SESSION 11 (4 Concurrent Topics)

HEALTH POLICY II

HP4   PRICING OF PHARMACEUTICALS IN CANADA AND EUROPE: A COMPARATIVE ANALYSIS
 Palmer WN, Palmer D'Angelo Consulting Inc, Ottawa, ON, Canada
HP5   USE OF THE SOJA METHOD FOR CHOOSING A HMG CO-A REDUCTASE INHIBITOR (STATIN) IN IRELAND
 Heerey A, McGowan B, Barry M National Centre for Pharmacoeconomics, Dublin, Ireland
HP6   THE IMPACT OF PIPELINE DRUGS ON UNITED STATES DRUG EXPENDITURE GROWTH TRENDS
 Mullins CD, Wang J, Palumbo FB, Stuart B University of Maryland, Baltimore, MD, USA

CANCER II

CN4   THE IMPACT OF THE DIAGNOSIS OF CANCER ON OUT-OF-POCKET HEALTH-CARE EXPENDITURES MADE BY THE US ELDERLY
 Langa K1, Hayman J1, Chernew M1, Slavin M2, Fendrick AM2, 1University of Michigan, Ann Arbor, MI, USA; 2Ortho Biotech, Raritan, NJ, USA
CN5   A SPECIFIC QUALITY OF LIFE SCALE IN UPPER LIMB LYMPHOEDEMA: THE ULL-27 QUESTIONNAIRE
 Launois R1, Megnigbeto A1, Le Lay K1, Alliot F2, 1REES France, PARIS, France; 2Clinique Hartmann, NEUILLY SUR SEINE, France
CN6   MENS' PREFERENCES FOR THE CONSERVATIVE MANAGEMENT OF NON-METASTATIC PROSTATE CANCER: THE USE OF CONJOINT ANALYSIS
 Sculpher M1, Bryan S2, Emberton M3, Fry P3, de Winter P3, Payne H3, 1University of York, York, UK; 2Birmingham University, Birmingham, UK; 3Middlsex Hospital, London, UK

CARDIOVASCULAR DISEASE II

CV4   COMPARISON BETWEEN INVESTIGATOR AND PATIENT'S GLOBAL HEALTH ASSESSMENTS USING CALCULATED HUI-III AND SF-36 UTILITY VALUES
 Hatoum HT1, Brazier JE2, Akhras KS3, Boyer JG3, Tooley JF3, 1Hind T Hatoum & Company, Chicago, IL, USA; 2University of Sheffield, Sheffield, UK; 3Pharmacia Corporation, Skokie, IL, USA
CV5   ORLISTAT IN OBESE TYPE 2 DIABETIC PATIENTS: ASSESSMENT OF LONG TERM OUTCOMES AND COST-EFFECTIVENESS
 Lamotte M1, Annemans LJ2, Lefever A3, Nechelput M3, Masure J3, 1HEDM, MEISE, Belgium; 2Ghent University, HEDM, MEISE, Belgium; 3Roche Belgium, BRUSSELS, Belgium
CV6   EXCESS MORBIDITY AND COST OF FAILING TO ACHIEVE TARGETS FOR BLOOD PRESSURE CONTROL IN THE ELDERLY
 Lloyd AC1, Hansson L2, Anderson PM2, Kopp ZS3, Buch J3, 1Fourth Hurdle Consulting Ltd, London, UK; 2University of Uppsala, Uppsala, Sweden; 3Pfizer Inc, New York, NY, USA

PRACTICAL DESIGN ISSUES

DS1   PATIENT-REPORTED OUTCOMES: A COMPARISON OF TWO DATA-CAPTURE METHODS
 Hufford MR1, Noe L2, 1Invivodata, Inc, Pittsburgh, PA, USA; 2Ovation Research Group, Highland Park, IL, USA
DS2   POWER CALCULATIONS FOR WIDELY USED PATIENT-REPORTED OUTCOMES (PRO) MEASURES IN WOMEN'S HEALTH TRIALS
 Abetz L1, Brandman J2, Plante M3, 1Mapi Values, Cheshire, UK; 2Pfizer Pharmaceutical Group, New York, NY, USA; 3Pfizer Inc, Ann Arbor, MI, USA
DS3   DESIGN AND ANALYSIS OF UNIT COST ESTIMATION STUDIES: HOW MANY TYPES OF HOSPITALIZATION? HOW MANY COUNTRIES?
 Glick HA1, Orzol SM1, Tooley JF2, Polsky D1, Mauskopf J3, 1University of Pennsylvania, Philadelphia, PA, USA; 2Pharmacia, Skokie, IL, USA; 3Research Triangle Institute, Research Triangle Park, NC, USA
12:30-14:00 LUNCH, EXHIBITS & CONTRIBUTED POSTER PRESENTATIONS - SESSION I
14:00-15:00 CONTRIBUTED WORKSHOP PRESENTATIONS - SESSION I (7 Concurrent Workshops)
WW1    PUBLISHING YOUR OWN PHARMACOECONOMIC AND OUTCOME TOOLS ON THE INTERNET: HOW TO CREATE WEB-BASED CALCULATORS, SPREADSHEETS, DECISION MODELS, AND INTERACTIVE QUESTIONNAIRES
 McGhan WF, University of the Sciences, Philadelphia, PA, USA
WW2    NUMBER NEEDED TO TREAT (NNT): IS IT A USEFUL BENCHMARK FOR THE EFFICIENCY OF THERAPIES?
 Caro J, Huybrechts K Caro Research Institute, Concord, MA, USA
WW3    BEYOND COST-EFFECTIVENESS: THE STRATEGIC VALUE OF PRODUCTIVITY-RELATED OUTCOMES IN CLINICAL TRIALS, BURDEN OF ILLNESS STUDIES, AND POST-MARKETING RESEARCH
 Ozminkowski RJ1, Goetzel RZ2, Crown WC3, Long SR2, 1The MEDSTAT Group, Inc, Ann Arbor, MI, USA; 2The MEDSTAT Group, Inc, Washington, DC, USA; 3The MEDSTAT Group, Inc, Cambridge, MA, USA
WW4    THE ROLE OF EXTRAPOLATION IN ECONOMIC EVALUATION: APPLICATION OF TECHNIQUES TO MEET EMERGING REQUIREMENTS
 Drummond MF1, McGuire A2, Chancellor JV3, 1University of York, York, UK; 2City University London, London, UK; 3Innovus Research (UK) Ltd, Amersham, UK
WW5    RESPONSIVENESS OF PATIENT REPORTED OUTCOMES IN CLINICAL TRIALS: ISSUES, ASSESSMENT STRATEGY, AND INTERPRETATION
 Arnould B, De la Loge C, Marquis P Mapi Values, Lyon, France
WW6    HOW TO DEAL WITH MULTIPLE OUTCOME MEASURES IN CLINICAL STUDIES?
 Krabbe PF1, Novák A2, 1University Medical Centre Nijmegen, Nijmegen, Netherlands; 2NV Organon, The Netherlands, Oss, Netherlands
WW7    WHICH DATA CAN WE GET? - THE EFFECT OF ELECTRONIC PATIENT RECORDS AND SECURITY REQUIREMENTS ON DATA AVAILABILITY
 Almarsdottir A, Thorhallsdottir I, Heimisdottir M deCODE genetics Inc, Reykjavik, Iceland
15:00-15:15 BREAK
15:15-16:15 CONTRIBUTED WORKSHOP PRESENTATIONS - SESSION II
(7 Concurrent Workshops)
WW8    THE AMCP FORMULARY SUBMISSION FORMAT: IMPLICATIONS FOR PHARMACOECONOMIC RESEARCH PROGRAMS
 Mauskopf JA1, Hocker SC2, 1RTI Health Solutions, Research Triangle Park, NC, USA; 2PAREXEL International, Baltimore, MD, USA
WW9    BUILDING A PHARMACOECONOMIC STRATEGY FOR A PRODUCT
 Chambers MG1, Nuijten MJ2, 1MEDTAP International, London, UK; 2MEDTAP International, Jisp, Netherlands
WW10    EXPERTS BOARD IN HEALTH ECONOMICS AND OUTCOMES RESEARCH: INSTRUCTIONS FOR USE
 Dinet J, Gabriel S, Cros S, Myon E, Taieb C Association CRééS, Fontenay-sous-Bois, France
WW11    THE USE OF INTEGER/LINEAR PROGRAMMING MODELS IN DECISION MAKING
 Earnshaw SR1, Dennett SL2, 1RTI Health Solutions, RTP, NC, USA; 2Eli Lilly, Indianapolis, IN, USA
WW12    BEYOND THE QALY: USING CONJOINT ANALYSIS TO QUANTIFY HEALTH-CARE PREFERENCES AND EQUIVALENT MONETARY VALUES
 Johnson FR1, Ratcliffe J2, 1Research Triangle Institute, Research Triangle Park, NC, USA; 2Research Triangle Institute, Manchester, UK
WW13    VISUAL ANALOG SCALES: DO THEY HAVE A ROLE IN THE MEASUREMENT OF PREFERENCES FOR HEALTH STATES?
 Torrance G1, Keresteci M2, 1McMaster University, Innovus Research Inc, Burlington, ON, Canada; 2Innovus Research Inc, Burlington, ON, Canada
WW14    MULTICULTURAL AND MULTILINGUAL QUALITY OF LIFE INSTRUMENT DEVELOPMENT: A COMPARISON OF SEQUENTIAL, PARALLEL AND SIMULTANEOUS APPROACHES AND THEIR IMPACT ON TRANSLATION AND ADAPTATION
 Eremenco SL1, Lent L1, Flood E2, 1Evanston Northwestern Healthcare, Evanston, IL, USA; 2MEDTAP International, Bethesda, MD, USA
16:30- 17:30 ISPOR CENTRAL & EASTERN EUROPEAN DISCUSSION GROUP FORUM
 

Moderator: Borislav Borissov MD, PhD, Executive Director, Bulgarian Drug Agency, Sofia, Bulgaria

Health Care Reform in Central and Eastern Europe: Focus on the Evolving Role of Health Economics in the Pricing and Reimbursement Process

Speaker: Agota Szende MSc, PhDc, Jozsef Kosa MD, MBA, Mark Nuijten MD, MBA, MEDTAP International, Amsterdam, The Netherlands

The First Steps of Pharmacoeconomics in Ukraine

Speaker:  Olga Zaliska BSc, Lviv Medical University, Lviv, Ukraine 

16:30-17:30 ISPOR MEDICAL DEVICE & DIAGNOSTICS FORUM
 

“The Evolution of Economic Evaluations and Outcomes Research for Medical Devices in Europe”

Moderator: Arne Heissel PhD, European Health Outcomes Manager, Ethicon Endo-Surgery (Europe), Norderstedt, Germany and former ISPOR Fellow

Welcome: Bryan Luce PhD, CEO, MEDTAP International, Bethesda, MD, USA, Past ISPOR President and ISPOR Medical Device and Diagnostics Council – North America Member

How and Why the Medical Device Industry is Focusing on Outcomes Research and Economic Evaluations

Speaker: Markus Siebert MS, Business Area Director, Economic Affairs, EUCOMED, Brussels, Belgium

Insurance Companies’ Use of Outcomes Research and Economic Evaluations in Decision-Making

Speaker: Patrick Galloo MD, CMO, Alliance of Social Sickness Funds, Brussels, Belgium

Integrating Economic Evaluations into Reimbursement Negotiations

Speaker: Volker Kruse, Director, Ethicon Endo-Surgery (Europe), Norderstedt, Germany

16:30-17:30 ISPOR QUALITY OF LIFE SPECIAL INTEREST GROUP (QoL SIG) FORUM
 

QUALITY OF LIFE OUTCOMES: CONTROVERSIAL ISSUES & PRACTICAL SOLUTIONS
Highlights of four important quality of life outcomes issues will be discussed including examples and applications. Presenters from the ISPOR QoL Special Interest Group will contribute practical solutions.
Moderator: Nancy Kline Leidy PhD, RN, MEDTAP International, Bethesda, Maryland, USA, and ISPOR QoL SIG Chair

  • IS IT QOL, HEALTH STATUS OR PATIENT PREFERENCE?
    Pennifer Erickson PhD, O.L.G.A., State College, PA, USA
    How have HrQoL, health status and patient preference been defined? What are the distinguishing features of each? When we review measures of each, will we know what we're looking at?
  • HOW DO WE WORK GLOBALLY?
    Diane Jacqueline Wild MSc, Oxford Outcomes, Oxford, UK & ISPOR QoL SIG Translation & Adaptation Chair
    What are the problems of measuring outcomes globally? How do we deal with translation issues? How do we know when we have cultural validity?
  • WHAT DO THE NUMBERS MEAN?
    Joyce Cramer, Yale University School of Medicine, West Haven, CT, USA & ISPOR QoL SIG Interpretation & Meaning Chair
    Do we need to know what magnitude of response can be considered "clinically meaningful" as opposed to "statistically significant"? How is this determined? How are the data used?
  • HOW DO WE PUT A VALUE ON QOL OUTCOMES?
    Paul Kind MPhil, University of York, Centre for Health Economics, York, UK & ISPOR QoL SIG Value & Valuation Chair

Values and preference are endemic in the design and use of HrQoL measures - but where do the numbers come from? Whose values/preferences are they and how are they derived? Whose should they be?

17:30 -18:30 ISPOR QUALITY OF LIFE GROUP DISCUSSIONS & RECEPTION
 
Each of the QoL SIG Subgroups will meet to discuss current initiatives.
  • QoL SIG Value & Valuation led by Paul Kind MPhil, ISPOR QoL SIG Value and Valuation Chair
  • QoL SIG Translation & Adaptation led by Diane Wild MSc, ISPOR QoL SIG Translation & Adaptation Chair
  • QoL SIG Concepts & Definitions led by Pennifer Erickson PhD, ISPOR QoL SIG Concepts & Definitions Chair
  • QoL SIG Interpretation & Meaning led by Joyce Cramer PhD, ISPOR QoL SIG Interpretation & Meaning Chair
17:30-18:30 EXHIBITORS' WINE & CHEESE RECEPTION & CONTRIBUTED POSTER PRESENTATIONS - SESSION II
  Sponsored by MEDTAP International

Fourth Annual European Conference Main Page